U103 The Evolving Toolbox for Treating Difficult Warts
DESCRIPTION
The “difficult wart” is a common problem in all dermatology practices. Thick, extensive, or cosmetically problematic locations may not be suitable or responsive to destructive modalities and pain can represent a significant barrier, especially in children. The evidence base for established therapies, (intralesional chemotherapy, topical and intralesional immunotherapy) and promising, new approaches (topical pharmacotherapies, heat-therapy, and non-thermal plasma) will be assessed with an emphasis on benefits and limitations in treating problematic lesions.
LEARNING OBJECTIVES
Strategically manage warts that are unresponsive to or cannot be managed with traditional treatments.
Compare the efficacy, safety, cost, benefits, and limitations of traditional, new, and evolving wart treatments.
DIRECTOR
Peter C. Friedman, MD, FAAD
DISCLOSURES
Peter C. Friedman, MD, FAAD
AbbVie – Investigator(Fees); Almirall – Consultant (1099 relationship)(Honoraria); Galderma – Advisory Board(Honoraria), Investigator(Fees), Speaker(Fees); Incyte – Investigator(Fees); Nielsen Bioscience, Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); VYNE Therapeutics – Investigator(Fees);